Public comment submitting Reuters story on PMI irregulatities in IQOS clinical studies to PMI MRTP docket

Lauren Lempert submitted this comment to FDA on December 20, 2017.  The comment Tracking Number is 1k1-90gh-rnjp.
 
Reuters published a special report on December 20, 2017 identifying several irregularities in Philip Morris' IQOS research. The kind of industry behavior documented in this report is questionable but not new, and FDA should consider this when making a determination on PMI's IQOS applications. See attached Reuters report and PMI's 10-Year Corporate Affairs Objectives & Strategies report discussed in Reuters report.
 
Uploaded File(s):

• Reuters Special Report-Scientists describe irregularities in PM's IQOS experiments.pdf
• Reuters report- PMI 10-Year Corporate Affairs Objectives & Strategies.pdf